{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:17:40Z","timestamp":1792113460951,"version":"4.4.0"},"reference-count":51,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2005,4,4]],"date-time":"2005-04-04T00:00:00Z","timestamp":1112572800000},"content-version":"vor","delay-in-days":1860,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Physiology"],"published-print":{"date-parts":[[2000,3]]},"abstract":"<jats:p>Synthetic oxytocin and vasopressin agonists and antagonists have become important tools for research and were instrumental in the identification of the four known receptor subtypes, V<jats:sub>1a<\/jats:sub>, V<jats:sub>2<\/jats:sub>, V<jats:sub>1b<\/jats:sub> (V<jats:sub>3<\/jats:sub>) and oxytocin, of these peptide hormones. However, the relative lack of receptor selectivity, particularly of the antagonists, has limited their usefulness as experimental probes and their potential as therapeutic agents. We now present some findings from our continuing studies aimed at the design of more selective oxytocin and vasopressin agonists and antagonists and a structure\u2010activity relationship update on our recently discovered novel hypotensive vasopressin peptides. Bioassays have been, and continue to be, of critical importance in leading to the discovery of the novel agonists, antagonists and hypotensive peptides reported here. This paper highlights three main aspects of these studies. (1) Replacement of the tyrosine<jats:sup>2<\/jats:sup> and\/or phenylalanine<jats:sup>3<\/jats:sup> residues in the V<jats:sub>2<\/jats:sub> agonist deamino,[Val<jats:sup>4<\/jats:sup>,D\u2010Arg<jats:sup>8<\/jats:sup>]arginine\u2010vasopressin (dVDAVP)by thienylalanine resulted in selective V<jats:sub>2<\/jats:sub> agonists with strikingly high potencies. However, the peptide solutions were unstable and lost activity over time. These highly potent V<jats:sub>2<\/jats:sub> agonists, which are devoid of vasopressor activity, are promising leads for improving drugs for treating diabetes insipidus, enuresis and coagulation disorders. (2) Diaminopropionic acid and diaminobutyric acid substitution at position\u20105 in oxytocin and in V<jats:sub>1a<\/jats:sub> antagonists yielded, respectively, the first specific antagonist for the oxytocin receptor, desGly\u2010NH<jats:sub>2<\/jats:sub>,d(CH<jats:sub>2<\/jats:sub>)<jats:sub>5<\/jats:sub>[D\u2010Trp<jats:sup>2<\/jats:sup>, Thr<jats:sup>4<\/jats:sup>, Dap<jats:sup>5<\/jats:sup>]OVT and the first specific antagonist for the vasopressin V<jats:sub>1a<\/jats:sub> receptor, d(CH<jats:sub>2<\/jats:sub>)<jats:sub>5<\/jats:sub>[Tyr(Me)<jats:sup>2<\/jats:sup>, Dab<jats:sup>5<\/jats:sup>]AVP. The availability of single receptor subtype\u2010specific or selective antagonists will enhance our ability to delineate receptor functions. Utilising these new receptor specific probes, we were able to show thatthe uterotonic action of vasopressin is mediated principally by oxytocin and not by V<jats:sub>1a<\/jats:sub> receptors. (3) Replacement of the phenylalanine<jats:sub>8<\/jats:sub> residue in the V<jats:sub>1a<\/jats:sub>\/V<jats:sub>2<\/jats:sub>\/oxytocin antagonist, d(CH<jats:sub>2<\/jats:sub>)<jats:sub>5<\/jats:sub>[D\u2010Tyr(Et)<jats:sup>2<\/jats:sup>, Val<jats:sup>4<\/jats:sup>]AVP, with arginine<jats:sup>3<\/jats:sup> yielded the novel, selective, hypotensive vasopressin peptide, d(CH<jats:sub>2<\/jats:sub>)<jats:sub>5<\/jats:sub>[D\u2010Tyr(Et)<jats:sup>2<\/jats:sup>, Arg<jats:sup>3<\/jats:sup>, Val<jats:sup>4<\/jats:sup>]AVP (Peptide I). Bioassay characterisations of Peptide I show that its vasodepressor action is independent of the peripheral autonomic, bradykinin, nitric oxide and prostaglandin systems and is not mediated by the known classical oxytocin and vasopressin receptors. These findings suggest the existence of a new vasopressin receptor subtype that may be relevant to the vasodilating action of vasopressin in regional vascular beds. Iodinatable hypotensive peptides have been synthesised and could be developed as markers for the putative new receptor. Ongoing structure\u2010activity relationship studies on Peptide I have led to more potent and selective hypotensive peptides for use as new research tools and as leads for the development of a new class of antihypertensive agents.<\/jats:p>","DOI":"10.1111\/j.1469-445x.2000.tb00003.x","type":"journal-article","created":{"date-parts":[[2005,4,4]],"date-time":"2005-04-04T10:08:24Z","timestamp":1112609304000},"source":"Crossref","is-referenced-by-count":31,"title":["Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays"],"prefix":"10.1113","volume":"85","author":[{"given":"W. Y.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nga Ching","family":"Wo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stoytcho","family":"Stoev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling Ling","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,4,4]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1560223"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198804073181403"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo-126-4-2095"},{"key":"e_1_2_1_5_1","first-page":"84","article-title":"Design of oxytocin antagonists with prolonged action: Potential tocolytic agents for the treatment of preterm labor","volume":"239","author":"Chan W. Y.","year":"1986","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"e_1_2_1_6_1","first-page":"999","article-title":"Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: New approaches for the design of potent tocolytics for preterm labor","volume":"277","author":"Chan W. Y.","year":"1996","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(96)70050-9"},{"key":"e_1_2_1_8_1","first-page":"451","volume":"449","author":"Chan W. Y.","year":"1998","journal-title":"Discovery of novel selective hypotensive vasopressin peptides: A new vasodilating vasopressin receptor"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702114"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1530\/jrf.0.1020337"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1906.sp001148"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-0115(93)90227-Y"},{"key":"e_1_2_1_13_1","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0021-9258(18)51704-X","article-title":"The synthesis and pharmacological study of 4\u2010decarbox\u2010amido\u2010oxytocin (4\u2010\u03b1\u2010aminobutyric acid\u2010oxytocin) and 5\u2010decarbox\u2010amido\u2010oxytocin (5\u2010alanine\u2010oxytocin)","volume":"239","author":"Du Vigneaud V.","year":"1964","journal-title":"Journal of Biological Chemistry"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja01647a089"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja01115a553"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)49238-1"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(88)90778-9"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00099a020"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-64-6-1129"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00272a002"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3011.1991.tb01406.x"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1948.tb00396.x"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-452813-0.50012-X"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/bip.360220165"},{"key":"e_1_2_1_25_1","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0021-9258(18)49340-4","article-title":"Arginine\u2010vasotocin, a synthetic analogue of the posterior pituitary hormones containing the ring of oxytocin and the side chain of vasopressin","volume":"233","author":"Katsoyannis P. G.","year":"1958","journal-title":"Journal of Biological Chemistry"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00178a003"},{"key":"e_1_2_1_27_1","first-page":"127","volume-title":"Handbook of Neurohypophyseal Hormone Analogs","author":"Lebl M.","year":"1987"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-70-4-1142"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00267a004"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-8129-1_8"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-0115(93)90220-3"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1387(199701)3:1<31::AID-PSC82>3.0.CO;2-Y"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00122a016"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3011.1995.tb00596.x"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/308652a0"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00343a009"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00099a018"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1993.tb55550.x"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.3109\/10799899909036676"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1387(199911)5:11<472::AID-PSC217>3.0.CO;2-A"},{"key":"e_1_2_1_41_1","first-page":"615","volume-title":"Peptides 1996","author":"Manning M.","year":"1998"},{"key":"e_1_2_1_42_1","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1110125"},{"key":"e_1_2_1_43_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1895.sp000565"},{"key":"e_1_2_1_44_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo-125-1-217"},{"key":"e_1_2_1_45_1","first-page":"210","article-title":"Biologic assays for oxytocin and vasopressin","volume":"9","author":"Sawyer W. H.","year":"1961","journal-title":"Methods in Medical Research"},{"key":"e_1_2_1_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/1841464a0"},{"key":"e_1_2_1_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1947.tb00336.x"},{"key":"e_1_2_1_48_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00242a012"},{"key":"e_1_2_1_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1387(199903)5:3<141::AID-PSC180>3.0.CO;2-6"},{"key":"e_1_2_1_50_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1850553"},{"key":"e_1_2_1_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1992.tb09058.x"},{"key":"e_1_2_1_52_1","doi-asserted-by":"publisher","DOI":"10.1135\/cccc19671250"}],"container-title":["Experimental Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1469-445X.2000.tb00003.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1469-445X.2000.tb00003.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/physoc.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1469-445X.2000.tb00003.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T07:43:29Z","timestamp":1698565409000},"score":1,"resource":{"primary":{"URL":"https:\/\/physoc.onlinelibrary.wiley.com\/doi\/10.1111\/j.1469-445X.2000.tb00003.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3]]},"references-count":51,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2000,3]]}},"alternative-id":["10.1111\/j.1469-445X.2000.tb00003.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-445x.2000.tb00003.x","archive":["Portico"],"relation":{},"ISSN":["0958-0670","1469-445X"],"issn-type":[{"value":"0958-0670","type":"print"},{"value":"1469-445X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,3]]}}}